培维索孟(Pegvisomant) - 药物靶点：GHR_在研适应症：肢端肥大症，胰岛素抵抗_专利_临床

概要

基本信息

药物类型

多肽激素

别名

pegviosomant、Pegvisomant (genetical recombination) (JAN)、Pegvisomant (USAN/INN)

+ [7]

靶点

GHR

作用方式

拮抗剂

作用机制

GHR拮抗剂(生长激素受体拮抗剂)

治疗领域

神经系统疾病内分泌与代谢疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

肢端肥大症胰岛素抵抗

非在研适应症

晚期恶性实体瘤白蛋白尿乳腺癌+ [5]

原研机构

Sensus USA, Inc.

在研机构

Pfizer Europe MA EEIG

Pfizer Inc.Pfizer SRL

+ [2]

非在研机构

Pfizer Ltd. (India)Pfizer Pharma GmbHPfizer ApS

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2002-11-12),

肢端肥大症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国)

登录后查看时间轴

结构/序列

Sequence Code 61626

来源: *****

关联

39

项与培维索孟相关的临床试验

NCT05470504

/ Recruiting临床2期IIT

Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance

Background:
Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems.
Objective:
To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance.
Eligibility:
Adults aged 18 to 65 years with either a known variant in the insulin receptor gene or with a diagnosis of partial LD.
Design:
Participants will have 2 hospital stays, about 1 month apart. Each stay will be 3 or 4 nights.
During each hospital stay, participants will have many tests. They will have a physical exam with blood tests. They will have all of their urine collected for a 24-hour period. They will have scans to measure their muscle, bone, and fat tissues. They will have tests to measure metabolism and insulin sensitivity. They may have an optional biopsy of fat tissue.
During the first hospital visit, participants will learn how to give themselves shots of a drug (pegvisomant) that blocks growth hormone. The drug is injected under the skin. Participants will continue to give themselves these shots once a day at home.
After the first hospital visit, participants will talk on the phone with members of the study team once each week. After 2 weeks they will have blood drawn for tests.
Participants will stop the shots after the second hospital visit.

开始日期2023-01-23

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

NCT05131100

/ RecruitingN/A

Korean Post-marketing Surveillance for Somavert

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

开始日期2022-07-13

申办/合作机构

Pfizer Inc.

CTIS2024-518214-11-01

/ Recruiting临床2期IIT

InvestiGating the rOle of Growth Hormone in hepatic lipid metabolism in humans

开始日期2022-01-01

申办/合作机构

Medical University of Vienna

100 项与培维索孟相关的临床结果

登录后查看更多信息

100 项与培维索孟相关的转化医学

登录后查看更多信息

100 项与培维索孟相关的专利（医药）

登录后查看更多信息

425

项与培维索孟相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment

Review

作者: Kossi, Sika Dédé ; Bronikowska, Małgorzata ; Schmidt, Fabian ; Gilis-Januszewska, Aleksandra ; Gueron, Beatrice ; Binowski, Grzegorz ; Jachimowicz, Michał

BACKGROUND:

Acromegaly is a rare and progressive condition caused by excessive secretion of growth hormone and insulin-like growth factor type 1. Pasireotide long-acting release (LAR) is indicated as a second-line therapy for adults with acromegaly who are unsuitable for or unresponsive to surgery and inadequately controlled with first-generation somatostatin receptor ligands (FGSRLs). Although its efficacy and safety have already been established, its cost-effectiveness remains unclear. The primary objective of this study was to systematically assess the cost-effectiveness of pasireotide LAR compared to other second-line medical options, particularly pegvisomant.

METHODS:

A systematic literature review was conducted in May 2024 in Medline, Medline In Process, Web of Science, and the Centre for Reviews and Dissemination (CRD), York. Studies were eligible if they were full or partial economic analyses of pasireotide LAR as a second-line pharmacological treatment for adult patients with acromegaly. Studies not available in English and publications prior to 2009 were excluded. Included articles were assessed for transparency using the appropriate checklists. Data extraction focused on costs, incremental cost-effectiveness ratios and quality-adjusted life years. Formal data synthesis of outcomes was not undertaken due to the small number of studies and notable heterogeneity between them. Methodological assessment involving the evaluation of model inputs, data sources, and their alignment with the evidence on the course of disease and clinical practice was performed to examine the main factors contributing to discrepancies in cost-effectiveness outcomes and assess the credibility of the results.

RESULTS:

Of 160 records identified, six publications met the inclusion criteria. Their findings demonstrated variability. The critical assessment highlighted considerable variability in methodological rigor among the included studies.

CONCLUSIONS:

Evidence on pasireotide LAR's cost-effectiveness versus pegvisomant regimens remains inconclusive. Although two studies indicated that pegvisomant is more cost-effective, the study with the highest methodological credibility found that pasireotide LAR is a cost-effective alternative.

2026-01-08·ENDOCRINOLOGY

Ghrelin-induced food intake in male mice requires peripheral extrahepatic GHR signaling

Article

作者: De Francesco, Pablo N ; Donato, Jose ; dos Santos, Willian O ; Wasinski, Frederick ; Kopchick, John J ; de Souza, Gabriel O ; Barrile, Franco ; Perelló, Mario ; Cornejo, María Paula

Abstract:

Ghrelin acts via the growth hormone secretagogue receptor (GHSR) and increases both food intake and growth hormone (GH) secretion. Studies in mice with genetic manipulations of GH receptor (GHR) revealed that GH action is required for ghrelin's orexigenic effects. However, the biological basis of this interdependence remains unclear. Here, we studied the mechanisms by which GHR contributes to ghrelin-induced hyperphagia in male mice. Transcriptomic analyses of single-cell datasets revealed that Ghr and Ghsr are co-expressed in a small subset of neurons, particularly within the hypothalamic arcuate nucleus (ARH). Systemic ghrelin administration increased food intake, circulating GH, and glycemia but did not induce GHR activation in the brain, as indicated by the absence of pSTAT5 immunoreactivity. Central GH administration failed to enhance ghrelin-induced food intake or glycemia. To evaluate the role of peripheral GHR signaling, we treated mice with the brain-impermeable GHR antagonist pegvisomant. Systemically injected pegvisomant impaired ghrelin's orexigenic effect without affecting its impact on glycemia or hypothalamic c-Fos activation, indicating that peripheral GHR signaling is required for ghrelin-induced hyperphagia. Pegvisomant did not alter refeeding-induced or AgRP neuron-mediated hyperphagia, suggesting a selective blockade of ghrelin's action. Moreover, ghrelin-induced food intake was preserved in hepatocyte-specific GHR knockout mice, despite disrupted hepatic GH signaling. Thus, peripheral, non-hepatic GHR signaling is selectively required for the orexigenic effects of ghrelin. This work reveals a critical GH-dependent, liver-independent mechanism underlying ghrelin-driven feeding, with potential implications for the neuroendocrine regulation of appetite and for therapeutic strategies targeting the ghrelin–GH axis in metabolic diseases.

2025-10-30·EUROPEAN JOURNAL OF ENDOCRINOLOGY

Medical treatment in acromegaly: a network meta-analysis

Review

作者: Haidich, Anna-Bettina ; Ilie, Mirela-Diana ; Anagnostis, Panagiotis ; Raverot, Gérald ; Dekkers, Olaf M ; Kaparounaki, Chrysi ; De Alcubierre, Dario ; Goulis, Dimitrios G ; Isidori, Andrea M

Abstract:

Objective:

Acromegaly is a rare disorder caused by a growth hormone-secreting pituitary adenoma. Clinical trial evidence for its management is limited. This study compared medical treatments for acromegaly through a network meta-analysis, assessing biochemical and radiological responses.

Design:

A systematic review and network meta-analysis were conducted following the preferred reporting items for systematic reviews and network meta-analyses guidelines and Cochrane Handbook recommendations (PROSPERO registration: CRD42023364373).

Methods:

PubMed, Scopus, and Web of Science were searched up to June 2024. Included studies were randomized controlled trials and nonrandomized studies evaluating the efficacy or safety of acromegaly treatments. Primary outcomes were the percentage of adjusted insulin-like growth factor 1 (IGF-1) normalization and tumor shrinkage.

Results:

Twenty-seven studies, involving 4131 patients and 11 treatments were included. Pegvisomant was the best treatment for IGF-1 normalization, followed by pasireotide LAR. Both outperformed first-generation somatostatin receptor ligands (SRLs) combined with dopamine agonists (odds ratio [OR], 1.83; 95% CIs, 1.37-2.46 and OR, 1.46; 95% CIs, 1.02-2.08, respectively; I2 = 41%). Octreotide LAR was superior to oral octreotide capsules (OR, 5.41; 95% CIs, 1.89-15.52). For tumor shrinkage, pasireotide LAR was more effective than SRLs (n = 1059; OR, 11.47; 95% CIs, 1.5-87.64; I2 = 0%). Methodological heterogeneity may have affected comparability.

Conclusions:

Our findings suggest pasireotide LAR and pegvisomant as the most effective treatments for IGF-1 normalization. Pasireotide LAR was the best treatment for tumor shrinkage, though the evidence base was limited, requiring cautious interpretation. Their potential role as first-line options after surgery requires further research. Clinical decisions should consider cost, safety, and patient-specific parameters to optimize outcomes.

4

项与培维索孟相关的新闻（医药）

2025-07-14

·PipelineReview

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO). The oral presentation, titled “Development of a Novel Growth Hormone Receptor Antagonist Antibody for the Treatment of Acromegaly,” highlights the significant potential of MAR002 to address critical unmet needs in patients suffering from this rare and highly morbid disease. Presentation highlights include: Marea Therapeutics has completed a GLP-toxicology study to assess MAR002’s safety. The preclinical pharmacology data strongly support advancing MAR002 into clinical development; a Phase 1 first-in-human study is expected to begin in the third quarter of 2025. Marea’s development strategy aims for rapid advancement into acromegaly patients after achieving proof of mechanism in healthy volunteers, with a clear path to approval guided by FDA guidance for IGF-1 normalization. “The preclinical data presented at ENDO 2025 underscore the potential of MAR002 to meaningfully transform the treatment landscape for acromegaly,” said Ethan Weiss, M.D., chief scientific officer of Marea Therapeutics. “With its strong potency, enhanced durability, and favorable developability profile, MAR002 is uniquely positioned to overcome the limitations of current therapies and offer a more effective, targeted approach for patients. We are excited to advance MAR002 into clinical development and bring forward a next generation and potential best-in-class GHR antagonist.” Marea Therapeutics believes MAR002 represents a significant opportunity to replace and expand the market for existing growth hormone receptor antagonists (GHRAs) and could also be used in combination with somatostatin receptor ligands (SRLs), offering a more effective and convenient treatment option for patients with acromegaly. About MAR002 MAR002 is a novel, potent and selective half-life-extended, allosteric, human monoclonal GHRA antibody being developed for the treatment of acromegaly. The PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly. About Acromegaly Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology. The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years. The current treatment paradigm for acromegaly often involves surgery, performed in over 90% of patients, which achieves remission in about 50% of cases, though this can degrade over time. Medical therapy is required for approximately 65% (around 20,000 in the U.S.) of patients during their disease journey, regardless of their surgical history. Current medical treatments include somatostatin receptor ligands (SRLs) and growth hormone receptor antagonists (GHRAs), such as pegvisomant. However, many patients do not achieve biochemical control with existing therapies. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for atherosclerotic cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X . SOURCE: Marea Therapeutics

临床2期孤儿药临床1期

2024-05-30

·蒲公英Ouryao

又有35个品规儿童药鼓励研发申报

转自：国家卫健委编辑：水晶5月30日，国家卫健委药物政策与基本药物制度司公示第五批鼓励研发申报儿童药品建议清单。公示清单共35个品规，这些品规是国内未注册上市且临床急需的儿童用药。35个第五批公示品规：阿尼芬净（注射剂）、柯拉特龙（乳膏剂）、头孢罗膦（注射剂）、艾伐卡托（颗粒剂）、阿托伐他汀混悬剂、达比加群酯（微丸）、索利那新（混悬剂）、托吡酯（口服溶液剂）、托法替布（口服溶液剂）、西替利嗪（注射剂）、伊伐雷定（口服溶液剂）、氨曲南（吸入溶液剂) 、甲苯磺酸托氟沙星（颗粒剂、片剂）、美替拉酮（胶囊剂）、谷卡匹酶（注射剂）、舒噻美（口服混悬液）、匹莫齐特（片剂）、培维索孟（注射液）、阿昔单抗（注射剂）、瑞斯利珠单抗（注射剂）、卡拉西珠单抗（注射剂）、艾哌依卡基（注射剂）、瑞利珠单抗（注射剂）。第四批24个品种：涉及30个品规、9种剂型，覆盖神经系统用药、消化道和新陈代谢用药、抗肿瘤药及免疫调节剂等治疗领域。<<详见24个品种！四部门联合印发（第四批）鼓励研发申报儿童药品清单>>前三批105种：2016年以来，国家卫生健康委会同有关部门，先后制定并发布了三批含105种药品的《鼓励研发申报儿童药品清单》。为进一步落实原国家卫生计生委等6部门《关于保障儿童用药的若干意见》要求，丰富儿童适用药品的品种、剂型和规格，满足儿科临床用药需求，2024年，国家卫生健康委、工业和信息化部和国家药监局继续紧密围绕我国儿童疾病谱以及相关企业研发生产能力，组织临床、药学、研发、注册等有关专家结合中国大陆境内尚未注册上市且临床急需的儿童用药现状，基于循证原则筛选论证，提出了《第五批鼓励研发申报儿童药品建议清单》。现予以公示，公示5个工作日。如有异议，请通过以下电话予以反映。电话：（010）68791740 附件：第五批鼓励研发申报儿童药品建议清单药物政策与基本药物制度司 2024年5月30日

上市批准

2024-03-19

·BioSpace

Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission

Pictured: Blood sample for insulin-like growth factor-1 (IGF-1)/iStock, Jarun011 Crinetics Pharmaceuticals has secured another late-stage win as its oral, once-daily investigational drug paltusotine aced a second Phase III study for acromegaly, a rare hormonal disorder. The biotech’s stock shot up over 10% Tuesday morning following the announcement. In the late-stage trial, 56% of patients taking paltusotine achieved the primary endpoint for the insulin-like growth factor 1 (IGF-1) level compared to 5% on placebo. The treatment also helped reduce symptoms of the disease—a secondary endpoint of the study. No serious adverse events were reported. Acromegaly, sometimes referred to as gigantism, is a serious hormonal disorder caused by a benign tumor in the pituitary gland that secretes growth hormone. Over 25,000 patients in the U.S. suffer from the rare disease, which results in enlargement of face, hands and feet. Left untreated, it can cause type 2 diabetes, hypertension, heart disease and other serious complications. Surgical removal of the tumor is the preferred treatment but many patients are not candidates for surgery. Current pharmacological options include painful monthly injections or Pfizer’s subcutaneous daily injection of Somavert. The Phase III data are the second positive trial results for Crinetics in acromegaly. In September 2023, the biotech shared data for a study of paltusotine in patients who switched from their current injections to Crinetics’ pill. Among treated patients, 83% were able to maintain their IGF-1 levels within the upper limit of normal, compared to only 4% of those on placebo. With these data in hand, Crinetics plans to submit its New Drug Application to the FDA in the second half of this year, while prepping for a 2025 launch. Jefferies analysts believe the market opportunity could be around $300 million for the company. Crinetics is also testing the drug candidate in carcinoid syndrome, reporting positive Phase II topline results last week. Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.

临床3期临床结果临床2期申请上市

100 项与培维索孟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05394	培维索孟	H01AX01	DB00082

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肢端肥大症	欧盟	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	冰岛	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	列支敦士登	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	挪威	Pfizer Europe MA EEIG	2002-11-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰岛素抵抗	临床3期	意大利	Pfizer SRL	2015-12-04
白蛋白尿	临床2期	英国	Pfizer Ltd. (India)	2004-09-04
糖尿病肾病	临床2期	英国	Pfizer Ltd. (India)	2004-09-04
乳腺癌	临床1期	美国	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	加拿大	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	芬兰	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	德国	Pfizer Inc.	2009-11-01
结直肠癌	临床1期	美国	Pfizer Inc.	2009-11-01
结直肠癌	临床1期	加拿大	Pfizer Inc.	2009-11-01
结直肠癌	临床1期	芬兰	Pfizer Inc.	2009-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (High Dose SRL + Weekly Pegvisomant)	選遞範遞鑰獵齋選壓選(糧蓋夢繭繭繭廠願艱廠) = 鏇顧餘獵憲餘餘鏇鹹簾餘繭顧觸廠醖淵鏇艱簾 (顧鹽衊膚範鑰築壓觸網, 1,645.49) 更多	-	2023-01-04
NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (Low Dose SRL + Daily Pegvisomant)	選遞範遞鑰獵齋選壓選(糧蓋夢繭繭繭廠願艱廠) = 製窪築積齋蓋網獵選衊餘繭顧觸廠醖淵鏇艱簾 (顧鹽衊膚範鑰築壓觸網, 11,158.49) 更多	-	2023-01-04
ENDO2020	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pegvisomant	願壓淵積蓋糧鹹艱顧鏇(鬱醖構糧範餘製膚鹽鑰) = 網網鏇夢鏇築廠糧簾鏇艱壓鹹艱獵積壓鑰壓廠 (鏇憲繭積壓觸衊製蓋廠 ) 更多	-	2020-05-08
ENDO2020	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pasireotide LAR	願壓淵積蓋糧鹹艱顧鏇(鬱醖構糧範餘製膚鹽鑰) = 夢製觸餘選觸鑰構繭構艱壓鹹艱獵積壓鑰壓廠 (鏇憲繭積壓觸衊製蓋廠 )	-	2020-05-08
SUN-LB079 (ENDO2019)	N/A	肢端肥大症	2,221	Pegvisomant	網製壓願醖夢憲淵築願(艱醖選觸夢範範糧鏇製) = 淵餘艱壓廠選鑰築鹹衊製簾製鹹壓鬱觸壓醖糧 (願膚壓簾齋衊鹹鏇壓鏇 ) 更多	-	2019-04-30
ACROSTUDY (ENDO2019)	N/A	肢端肥大症	110	Pegvisomant	壓淵獵製製獵艱構網簾(窪製簾範衊製獵襯齋窪) = 齋繭鹽衊淵築遞衊鏇築糧夢觸繭壓襯鹹鬱網顧 (願蓋鏇顧積夢襯襯膚夢, 5.4 ~ 6.1)	-	2019-04-30
NCT01261000 (CTgov)	N/A	肢端肥大症	8	Pegvisomant	淵壓膚觸餘壓獵網衊遞(醖餘鏇衊範艱廠糧繭窪) = 夢窪鬱鑰壓憲蓋顧蓋築窪獵獵夢糧憲窪廠膚製 (夢齋遞選鑰糧範淵蓋觸, 107.33) 更多	-	2017-08-22
NCT02023918 (PEGIR, CTgov)	临床2期	代谢综合征 \| 糖尿病前期	6	pegvisomant	壓構繭襯鏇齋觸選窪鏇(壓鏇簾願觸鏇鹹積網蓋) = 憲壓壓淵繭選築鏇製夢鏇壓選網鹽膚壓鹽淵襯 (窪範網壓鹽鹹製襯繭膚, 1.46) 更多	-	2017-03-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 10 mg)	範鏇鏇繭鑰壓淵淵蓋蓋 = 觸窪築鏇糧選獵鹹構構艱遞衊遞鬱觸鬱蓋積壓 (遞鬱糧顧淵網齋餘願築, 獵範夢淵醖遞範顧齋範 ~ 膚選網艱鹽選夢積膚網) 更多	-	2013-12-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 20 mg)	範鏇鏇繭鑰壓淵淵蓋蓋 = 顧遞膚鏇齋積糧淵選窪艱遞衊遞鬱觸鬱蓋積壓 (遞鬱糧顧淵網齋餘願築, 簾選積築簾願範艱獵憲 ~ 鬱壓壓簾夢繭糧製襯淵) 更多	-	2013-12-13
NCT00969644 (Pubmed \| Andrology)	N/A	-	8	GH treatment	鑰簾餘膚網獵顧壓襯網(繭淵壓製遞觸夢壓顧糧) = 壓夢憲觸顧憲製蓋製製製遞製糧繭餘獵窪願夢 (夢衊餘壓簾夢選糧蓋構 ) 更多	-	2013-07-01
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR (Sandostatin LAR High Dose Alone)	餘顧齋範鏇鬱夢壓觸壓 = 築淵鹹遞簾鹹艱淵簾網衊顧鹽鏇淵艱餘壓襯憲 (積網艱夢鹽積範艱淵壓, 網淵餘獵繭艱鏇築觸簾 ~ 簾鹽鏇餘觸繭蓋觸願鑰) 更多	-	2011-02-17
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR+pegvisomant (Sandostatin LAR High Dose + Pegvisomat)	餘顧齋範鏇鬱夢壓觸壓 = 築觸製鏇壓選觸鹽鑰顧衊顧鹽鏇淵艱餘壓襯憲 (積網艱夢鹽積範艱淵壓, 繭選範簾廠鏇觸獵鑰網 ~ 獵窪顧餘範鬱願糧製築) 更多	-	2011-02-17